Developing both prophylactic 
and therapeutic effective 
countermeasures

Crimean Congo Haemorrhagic Fever 
Vaccine & Immunotherapy

The CCHFVACIM project aims to address the serious public health threat posed by Crimean Congo Haemorrhagic Fever Virus (CCHFV), a tick-borne zoonotic virus that causes fatal epidemics in humans. This is one of the most threatening vector-borne pathogens, widely distributed, including on the European continent. Currently, there are no preventive or effective therapeutic measures available against CCHFV, which is listed as a key priority in the WHO’s R&D Blueprint list of infectious agents with epidemic or pandemic potential.

Deep structural biology studies on viral glycoproteins and investigation of the immunogenicity of the viral antigens will be combined with optimisation of a mRNA vaccine candidate against the virus and characterisation of the resulting protective immunity, as well as with the development of immuno-therapeutic monoclonal antibodies (mAbs) based on CCHFV’s antigenic targets.


Numbers

0

partners

0

countries

0

years EU-funded

project

0M

€

News

  • News from the CCHFVACIM project !

    Watch our second video.

  • New Publication

    New CCHFVACIM-supported study sheds light on CCHFV infection dynamics in sheep A new study supported by the CCHFVACIM project provides detailed insights into how Crimean-Congo haemorrhagic fever virus (CCHFV) disseminates in sheep and how the animals’ immune response develops over time. Published in npj Viruses, the study was led by researchers from the Friedrich-Loeffler-Institut, with…

  • What is CCHFVACIM project ?

    Watch our new video.